<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Reviews on Clinical Pharmacology and Drug Therapy</journal-id><journal-title-group><journal-title xml:lang="en">Reviews on Clinical Pharmacology and Drug Therapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Обзоры по клинической фармакологии и лекарственной терапии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1683-4100</issn><issn publication-format="electronic">2542-1875</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">694205</article-id><article-id pub-id-type="doi">10.17816/RCF694205</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original study articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Disturbances of hormonal status and ovulation process in infantile female rats with polycystic ovary syndrome induced by dehydroepiandrosterone</article-title><trans-title-group xml:lang="ru"><trans-title>НАРУШЕНИЯ ГОРМОНАЛЬНОГО СТАТУСА И ПРОЦЕССА ОВУЛЯЦИИ У ИНФАНТИЛЬНЫХ САМОК КРЫС С СИНДРОМОМ ПОЛИКИСТОЗНЫХ ЯИЧНИКОВ, ИНДУЦИРОВАННЫМ ДЕГИДРОЭПИАНДРОСТЕРОНОМ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6555-9540</contrib-id><contrib-id contrib-id-type="spin">6925-1558</contrib-id><name-alternatives><name xml:lang="en"><surname>Derkach</surname><given-names>Kira V.</given-names></name><name xml:lang="ru"><surname>Деркач</surname><given-names>Кира Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>derkatch_k@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-4240-4604</contrib-id><name-alternatives><name xml:lang="en"><surname>Pechalnova</surname><given-names>Alena S.</given-names></name><name xml:lang="ru"><surname>Печальнова</surname><given-names>Алена Сергеевна</given-names></name></name-alternatives><email>pechalnova.alena@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2252-0088</contrib-id><contrib-id contrib-id-type="spin">3489-8842</contrib-id><name-alternatives><name xml:lang="en"><surname>Morina</surname><given-names>Irina Yu.</given-names></name><name xml:lang="ru"><surname>Морина</surname><given-names>Ирина Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Biology)</p></bio><bio xml:lang="ru"><p>канд. биол. наук</p></bio><email>irinamorina@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-7997-0081</contrib-id><name-alternatives><name xml:lang="en"><surname>Fedorchuk</surname><given-names>Irina V.</given-names></name><name xml:lang="ru"><surname>Федорчук</surname><given-names>Ирина Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>fedorchuk1969@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7328-2120</contrib-id><contrib-id contrib-id-type="spin">3195-4135</contrib-id><name-alternatives><name xml:lang="en"><surname>Zorina</surname><given-names>Inna I.</given-names></name><name xml:lang="ru"><surname>Зорина</surname><given-names>Инна Игоревна</given-names></name></name-alternatives><email>zorina.inna.spb@gmail.com</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-4067-6673</contrib-id><name-alternatives><name xml:lang="en"><surname>Nagornyuk</surname><given-names>Kristina Ya.</given-names></name><name xml:lang="ru"><surname>Нагорнюк</surname><given-names>Кристина Яновна</given-names></name></name-alternatives><email>kristy-nagornuk@bk.ru</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0348-0631</contrib-id><contrib-id contrib-id-type="spin">8891-8186</contrib-id><name-alternatives><name xml:lang="en"><surname>Romanova</surname><given-names>Irina V.</given-names></name><name xml:lang="ru"><surname>Романова</surname><given-names>Ирина Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Biology)</p></bio><bio xml:lang="ru"><p>д-р биол. наук</p></bio><email>irinaromanova@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4293-3162</contrib-id><contrib-id contrib-id-type="spin">6335-8311</contrib-id><name-alternatives><name xml:lang="en"><surname>Shpakov</surname><given-names>Alexander O.</given-names></name><name xml:lang="ru"><surname>Шпаков</surname><given-names>Александр Олегович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Biology)</p></bio><bio xml:lang="ru"><p>д-р биол. наук</p></bio><email>alex_shpakov@list.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Федеральное государственное бюджетное учреждение науки Институт эволюционной физиологии и биохимии им. И. М. Сеченова Российской академии наук</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Институт эволюционной физиологии и биохимии им. И.М. Сеченова Российской академии наук</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Институт эволюционной физиологии и биохимии им. И.М. Сеченова Российской академии наук</institution></aff></aff-alternatives><aff id="aff4"><institution></institution></aff><pub-date date-type="preprint" iso-8601-date="2026-02-07" publication-format="electronic"><day>07</day><month>02</month><year>2026</year></pub-date><volume>1</volume><issue>1</issue><issue-title xml:lang="ru"/><history><date date-type="received" iso-8601-date="2025-10-26"><day>26</day><month>10</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2026-02-07"><day>07</day><month>02</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; , Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; , Эко-Вектор</copyright-statement><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.eco-vector.com/RCF/article/view/694205">https://journals.eco-vector.com/RCF/article/view/694205</self-uri><abstract xml:lang="en"><p><bold><italic>BACKGROUND: </italic></bold>Rodent models of polycystic ovary syndrome (PCOS), including those induced by dehydroepiandosterone (DHEA), are used to study the pathogenesis of polycystic ovary syndrome (PCOS). However, ovarian steroidogenesis and ovulation markers in this model remain poorly understood. There are no data on the ability of luteinizing hormone (LH) receptor agonists to stimulate ovulation in rats with this PCOS model, which is important for assisted reproductive technologies.</p> <p><bold><italic>AIM:</italic></bold><italic> </italic>To study ovarian steroidogenesis, ovulation markers, and ovarian morphology in infantile female rats with DHEA-induced PCOS and to evaluate the effect of the TP03 allosteric agonist, 5-amino-<italic>N-tert</italic>-butyl-2-(methylsulfanyl)-4-(3-(nicotinamido)phenyl)thieno[2,3-d]-pyrimidine-6-carboxamide, on these parameters.</p> <p><bold><italic>METHODS:</italic></bold><italic> </italic>Female Wistar rats, starting at 23–26 days of age, were treated with DHEA (6 mg/100 g/day, subcutaneously) for 6 weeks. Body and ovarian weights, blood testosterone, progesterone, and estradiol levels (ELISA), ovarian gene expression (RT-PCR), and ovarian morphology (number of tertiary and preovulatory follicles, <italic>corpora lutea</italic>, and follicular cysts) were assessed microscopically. To stimulate ovulation, PCOS rats were treated with Follimag (15 IU/rat) and after 48 hours with TP03 (25 mg/kg), after 16 hours the studied parameters were assessed.</p> <p><bold><italic>RESULTS:</italic></bold><italic> </italic>In DHEA-treated rats, ovarian weight, the number of tertiary follicles and corpora lutea from previous cycles, progesterone levels, and the expression of genes responsible for steroidogenesis (<italic>Star, Cyp11a1, Cyp17a1</italic>) and ovulation (<italic>Adamts-1, Vegf-a</italic>) decreased. Testosterone levels increased, and follicular cysts were detected, consistent with the pathogenesis of PCOS. Treatment with Follimag and TP03 increased ovarian weight, progesterone levels, and cytochrome CYP17A1 gene expression, and stimulated ovulation by inducing the formation of <italic>corpora lutea</italic>. Additionally, luteinized unruptured follicles were detected in the ovaries, which was associated with decreased expression of the metalloproteinase ADAMTS-1 and VEGF-A genes, which are involved in follicular rupture.</p> <p><bold><italic>CONCLUSION: </italic></bold>Treatment of infantile rats with DHEA-induced PCOS with TP03 induces ovulation and, in addition to normal <italic>corpora lutea</italic>, luteinized unruptured follicles are formed as a result of decreased expression of genes involved in follicle rupture.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Для изучения патогенеза синдрома поликистозных яичников (СПКЯ) применяют его модели на грызунах, в том числе индуцированные дегидроэпиандостероном (ДГЭА), но показатели овариального стероидогенеза и маркеры овуляции в этом случае изучены недостаточно. Отсутствуют данные о способности агонистов рецептора лютеинизирующего гормона (ЛГ) стимулировать овуляцию у крыс с этой моделью СПКЯ, что важно для вспомогательных репродуктивных технологий.</p> <p><bold>Цель исследования. </bold>Изучить овариальный стероидогенез, маркеры овуляции и морфологию яичников у инфантильных самок крыс с СПКЯ, индуцированным ДГЭА, оценить влияние на эти показатели аллостерического агониста TP03, 5-амино-<italic>N</italic>-<italic>трет</italic>-бутил-2-(метилсульфанил)-4-(3-(никотинамидо)фенил)тиено[2,3-d]-пиримидин-6-карбоксамида.</p> <p><bold>Методы. </bold>Самок крыс Wistar, начиная с возраста 23–26 дней, в течение 6 недель обрабатывали ДГЭА (6 мг/100 г/сутки, п/к), оценивая у них массу тела и яичников, уровни тестостерона, прогестерона и эстрадиола в крови (ИФА), экспрессию овариальных генов (RT-ПЦР), а также морфологию яичников (число третичных и предовуляторных фолликулов, желтых тел, фолликулярных кист) с помощью микроскопии. Для стимуляции овуляции СПКЯ-крыс обрабатывали Фоллимагом (15 МЕ/крысу) и через 48 ч TP03 (25 мг/кг), через 16 ч оценивали исследуемые показатели.</p> <p><bold>Результаты. </bold>У ДГЭА-крыс снижались масса яичников, число третичных фолликулов и желтых тел предыдущих циклов, уровень прогестерона, экспрессия генов, ответственных за стероидогенез (<italic>Star</italic>, <italic>Cyp11</italic><italic>a1</italic>, <italic>Cyp17</italic><italic>a1</italic>) и овуляцию (<italic>Adamts-1</italic>, <italic>Vegf-</italic><italic>a</italic>), повышался уровень тестостерона, в яичниках выявлялись фолликулярные кисты, что соответствует патогенезу СПКЯ. Обработка Фоллимагом и TP03 повышала массу яичников, уровень прогестерона и экспрессию гена цитохрома CYP17A1, стимулировала овуляцию, вызывая образование желтых тел. В яичниках также выявлялись лютеинизированные неразорвавшиеся фолликулы, что было ассоциировано со снижением экспрессии генов металлопротеиназы ADAMTS-1 и фактора VEGF-A, участвующих в процессе разрыва фолликула.</p> <p><bold>Заключение. </bold>Обработка инфантильных крыс с ДГЭА-индуцированным СПКЯ с помощью TP03 вызывает овуляцию, причем, наряду с нормальными желтыми телами, образуются лютенинизированные неразорвавшиеся фолликулы, как результат снижения экспрессии генов, вовлеченных в разрыв фолликула.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Polycystic ovary syndrome</kwd><kwd>dehydroepiandrosterone</kwd><kwd>rats</kwd><kwd>ovarian steroidogenesis</kwd><kwd>ovulation</kwd><kwd>allosteric agonist</kwd><kwd>progesterone</kwd><kwd>corpora lutea</kwd><kwd>luteinized unruptured follicle</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>Синдром поликистозных яичников</kwd><kwd>дегидроэпиандростерон</kwd><kwd>крысы</kwd><kwd>овариальный стероидогенез</kwd><kwd>овуляция</kwd><kwd>аллостерический агонист</kwd><kwd>прогестерон</kwd><kwd>желтое тело</kwd><kwd>лютеинизированный неразорвавшийся фолликул</kwd></kwd-group><funding-group><funding-statement xml:lang="en">Russian Science Foundation, project #19-75-20122</funding-statement><funding-statement xml:lang="ru">Российский научный фонд, проект № 19-75-20122</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Azziz R. Polycystic Ovary Syndrome. Obstet Gynecol. 2018;132(2):321-336. doi: 10.1097/AOG.0000000000002698</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469. doi: 10.1210/clinem/dgad463</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Helvaci N, Yildiz BO. Current and emerging drug treatment strategies for polycystic ovary syndrome. Expert Opin Pharmacother. 2023;24(1):105-120. doi: 10.1080/14656566.2022.2108702</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Liang Y, Zhang Q, Lou Z. Effect of pre-treatment with oral short-acting contraceptives on assisted reproductive technology outcomes in patients with polycystic ovary syndrome: a meta-analysis. Front Endocrinol (Lausanne). 2025;16:1545508. doi: 10.3389/fendo.2025.1545508</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Fitz VW, Mahalingaiah S. Optimization of assisted reproductive technology outcomes in patients with polycystic ovarian syndrome: updates and unanswered questions. Curr Opin Endocrinol Diabetes Obes. 2022;29(6):547-553. doi: 10.1097/MED.0000000000000780</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Sun B, Ma Y, Li L, et al. Factors Associated with Ovarian Hyperstimulation Syndrome (OHSS) Severity in Women With Polycystic Ovary Syndrome Undergoing IVF/ICSI. Front Endocrinol (Lausanne). 2021;11:615957. doi: 10.3389/fendo.2020.615957</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Khamaiseh K, Bdeir R, Abukbeer MM, et al. Impact of Polycystic Ovary Syndrome Hyperandrogenic Phenotypes A and Non-Hyperandrogenic D on Pregnancy Outcomes After in vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI). Int J Womens Health. 2025;17:561-569. doi: 10.2147/IJWH.S500692</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Corrie L, Gulati M, Singh SK, et al. Recent updates on animal models for understanding the etiopathogenesis of polycystic ovarian syndrome. Life Sci. 2021;280:119753. doi: 10.1016/j.lfs.2021.119753</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Muthukumaran D, Kumar J, Shanmugam R. Inducing agents and PCOS - A comprehensive analysis. J Steroid Biochem Mol Biol. 2025;254:106840. doi: 10.1016/j.jsbmb.2025.106840</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Ding H, Zhang J, Zhang F, et al. Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2021;12:741764. doi: 10.3389/fendo.2021.741764</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Mallya P, Kalthur G, Sravani AB, Lewis SA. Improving the Dehydroepiandrosterone Induced PCOS Rat Model: Interplay of Age, High Fat Diet, and Treatment Regimen on Reproductive and Metabolic Phenotypes. Reprod Sci. 2025;32(1):187-199. doi: 10.1007/s43032-024-01742-1</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Singh P, Srivastava RK, Krishna A. Effects of gonadotropin-releasing hormone agonist and antagonist on ovarian activity in a mouse model for polycystic ovary. J Steroid Biochem Mol Biol. 2016;163:35-44. doi: 10.1016/j.jsbmb.2016.03.034.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Shpakov AO. Hormonal and Allosteric Regulation of the Luteinizing Hormone/Chorionic Gonadotropin Receptor. Front Biosci (Landmark Ed). 2024;29(9):313. doi: 10.31083/j.fbl2909313 EDN: VVUGMQ</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Derkach KV, Lebedev IA, Morina IY, et al. Comparison of Steroidogenic and Ovulation-Inducing Effects of Orthosteric and Allosteric Agonists of Luteinizing Hormone/Chorionic Gonadotropin Receptor in Immature Female Rats. Int J Mol Sci. 2023;24(23):16618. doi: 10.3390/ijms242316618 EDN: ZLMODM</mixed-citation></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Derkach KV, Bakhtyukov AA, Sorokoumov VN, et al.Dynamics of gonadotropin and thienopyrimidine derivative TP03 effects on ovulation and ovarian steroidogenesis in Follimag-stimulated immature female rats. Reviews on Clinical Pharmacology and Drug Therapy. 2024;22(1):53–65. doi: https://doi.org/10.17816/RCF622883</mixed-citation><mixed-citation xml:lang="ru">Деркач КВ, Бахтюков АА, Сорокоумов ВН, и др. Динамика стимулирующих эффектов гонадотропина и тиенопиримидинового производного TP03 на овуляцию и овариальный стероидогенез у неполовозрелых самок крыс, с применением фолликулостимулирующего гормона. Обзоры по клинической фармакологии и лекарственной терапии. 2024;22(1):53–65. doi.org/10.17816/RCF622883 EDN: LCTBHE</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><mixed-citation>Bakhtyukov AA, Derkach KV, Fokina EA, et al. Effect of Different Luteinizing Hormone Receptor Agonists on Ovarian Steroidogenesis in Mature Female Rats. J. Evol. Biochem. Physiol. 2023;59(1):57–68. doi: 10.1134/S0022093023010052 EDN: GXGBYH</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ajayi AF, Akhigbe RE. Staging of the estrous cycle and induction of estrus in experimental rodents: an update. Fertil Res Pract. 2020;6:5. doi: 10.1186/s40738-020-00074-3</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>He Y, Li X, Li Y, et al. Dehydroepiandrosterone with a high-fat diet treatment at inducing polycystic ovary syndrome in rat model. Steroids. 2024;206:109424. doi: 10.1016/j.steroids.2024.109424</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Sander V, Luchetti CG, Solano ME, et al. Role of the N, N'-dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone. Reproduction. 2006;131(3):591-602. doi: 10.1530/rep.1.00941. PMID: 16514202.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Poojary PS, Nayak G, Panchanan G, et al. Distinctions in PCOS Induced by Letrozole Vs Dehydroepiandrosterone With High-fat Diet in Mouse Model. Endocrinology. 2022;163(9):bqac097. doi: 10.1210/endocr/bqac097</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2004;82(3):661-665. doi: 10.1016/j.fertnstert.2004.01.041</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Teede HJ, Joham AE, Paul E, et al. Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity (Silver Spring). 2013;21(8):1526-1532. doi: 10.1002/oby.20213</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Seow KM, Ting CH, Huang SW, et al. The use of dehydroepiandrosterone-treated rats is not a good animal model for the study of metabolic abnormalities in polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2018;57(5):696-704. doi: 10.1016/j.tjog.2018.08.015</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Stener-Victorin E, Padmanabhan V, Walters KA, et al. Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome. Endocr Rev. 2020;41(4):bnaa010. doi: 10.1210/endrev/bnaa010</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Peng F, Hu Y, Peng S, et al. Apigenin exerts protective effect and restores ovarian function in dehydroepiandrosterone induced polycystic ovary syndrome rats: a biochemical and histological analysis. Ann Med. 2022;54(1):578-587. doi: 10.1080/07853890.2022.2034933</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Ye Y, Zhou W, Ren Y, et al. The ameliorating effects of Guizhi Fuling Wan combined with rosiglitazone in a rat ovarian model of polycystic ovary syndrome by the PI3K/AKT/NF-κB and Nrf2/HO-1 pathways. Gynecol Endocrinol. 2023;39(1):2254848. doi: 10.1080/09513590.2023.2254848</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Elfiky AM, Ibrahim RS, Khattab AR, et al. Exploring the therapeutic potential of marjoram (Origanum majorana L.) in polycystic ovary syndrome: insights from serum metabolomics, network pharmacology and experimental validation. BMC Complement Med Ther. 2025;25(1):67. doi: 10.1186/s12906-025-04774-5</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Basheer M, Bhat AH, Ahmad Hajam Y, et al. Melatonin as a promising therapeutic intervention for restoring ovarian function in letrozole-induced polycystic ovary syndrome rats. Heliyon. 2023;9(11):e21237. doi: 10.1016/j.heliyon.2023.e21237</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Yang Y, Liu B, Wu G, Yang J. Exploration of the value of progesterone and progesterone/estradiol ratio on the hCG trigger day in predicting pregnancy outcomes of PCOS patients undergoing IVF/ICSI: a retrospective cohort study. Reprod Biol Endocrinol. 2021;19(1):184. doi: 10.1186/s12958-021-00862-6</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Jin H, Yang H, Zheng J, et al. Risk factors for low oocyte retrieval in patients with polycystic ovarian syndrome undergoing in vitro fertilization. Reprod Biol Endocrinol. 2023;21(1):66. doi: 10.1186/s12958-023-01118-1</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Arvis P, Lehert P, Guivarc'h-Levêque A. Both high and low HCG day progesterone concentrations negatively affect live birth rates in IVF/ICSI cycles. Reprod Biomed Online. 2019;39(5):852-859. doi: 10.1016/j.rbmo.2019.07.001</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>van de Lagemaat R, Timmers CM, Kelder J, et al. Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor. Hum Reprod. 2009;24(3):640-648. doi: 10.1093/humrep/den412</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Gerrits M, Mannaerts B, Kramer H, et al. First evidence of ovulation induced by oral LH agonists in healthy female volunteers of reproductive age. J Clin Endocrinol Metab. 2013;98(4):1558-1566. doi: 10.1210/jc.2012-3404</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Salehi R, Mazier HL, Nivet AL, et al. Ovarian mitochondrial dynamics and cell fate regulation in an androgen-induced rat model of polycystic ovarian syndrome. Sci Rep. 2020;10(1):1021. doi: 10.1038/s41598-020-57672-w</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Hossain MM, Cao M, Wang Q, et al. Altered expression of miRNAs in a dihydrotestosterone-induced rat PCOS model. J Ovarian Res. 2013;6(1):36. doi: 10.1186/1757-2215-6-36</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Foong SC, Abbott DH, Zschunke MA, et al. Follicle luteinization in hyperandrogenic follicles of polycystic ovary syndrome patients undergoing gonadotropin therapy for in vitro fertilization. J Clin Endocrinol Metab. 2006;91(6):2327-2333. doi: 10.1210/jc.2005-2142</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Geng T, Sun Y, Cheng L, et al. Downregulation of LHCGR Attenuates COX-2 Expression and Induces Luteinized Unruptured Follicle Syndrome in Endometriosis. Front Endocrinol (Lausanne). 2022;13:853563. doi: 10.3389/fendo.2022.853563</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Russell DL, Brown HM, Dunning KR. ADAMTS proteases in fertility. Matrix Biol. 2015;44-46:54-63. doi: 10.1016/j.matbio.2015.03.007</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Kushawaha B, Pelosi E. Spotlight on Proteases: Roles in Ovarian Health and Disease. Cells. 2025;14(12):921. doi: 10.3390/cells14120921</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Mittaz L, Russell DL, Wilson T, et al. Adamts-1 is essential for the development and function of the urogenital system. Biol Reprod. 2004;70(4):1096-10105. doi: 10.1095/biolreprod.103.023911</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Hazzard TM, Xu F, Stouffer RL. Injection of soluble vascular endothelial growth factor receptor 1 into the preovulatory follicle disrupts ovulation and subsequent luteal function in rhesus monkeys. Biol Reprod. 2002;67(4):1305-1312. doi: 10.1095/biolreprod67.4.1305</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Xie Y, Guo W, Shen X, et al. A delayed ovulation of progestin-primed ovarian stimulation (PPOS) by downregulating the LHCGR/PGR pathway. iScience. 2023;26(8):107357. doi: 10.1016/j.isci.2023.107357</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Lee C, Chen R, Sun G, et al. VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway. Signal Transduct Target Ther. 2023;8(1):305. doi: 10.1038/s41392-023-01539-9</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Szczuko M, Kikut J, Komorniak N, et al. The Role of Arachidonic and Linoleic Acid Derivatives in Pathological Pregnancies and the Human Reproduction Process. Int J Mol Sci. 2020;21(24):9628. doi: 10.3390/ijms21249628</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Huang R, Xue X, Li S, et al. Alterations of polyunsaturated fatty acid metabolism in ovarian tissues of polycystic ovary syndrome rats. J Cell Mol Med. 2018;22(7):3388-3396. doi: 10.1111/jcmm.13614. Epub 2018 Mar 30</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Shah SF, Noorali S, Faizi S, Jabeen A. Patuletin Ameliorates Inflammation and Letrozole-Induced Polycystic Ovarian Syndrome in Rats. Cell Biochem Funct. 2024;42(7):e4123. doi: 10.1002/cbf.4123</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Kokabiyan Z, Yaghmaei P, Jameie SB, Hajebrahimi Z. Therapeutic Effects of Eugenol in Polycystic Ovarian Rats Induced by Estradiol Valerate: A Histopathological and A Biochemical Study. Int J Fertil Steril. 2022;16(3):184-191. doi: 10.22074/ijfs.2021.537724.1176</mixed-citation></ref></ref-list></back></article>
